Celestica Inc. (CLS) Balance Sheet

The balance sheet is expanding rapidly, with total assets growing from $6.2B in 2025Q2 to $9.8B in 2026Q2, a 58% increase. This growth is primarily funded by a surge in liabilities, which rose from $4.5B to $7.3B, while equity grew from $1.8B to $2.5B. The PPE increase from $672.9M to $1.2B indicates heavy investment in manufacturing capacity, aligning with the capex surge noted in the cash flow statement. This suggests management is positioning for sustained hyperscaler demand, but the pace of asset growth may outpace near-term revenue, potentially pressuring returns on assets.

While D/E has increased from 0.50 in 2025Q2 to 0.33 in 2026Q2, this is still low compared to peers like Jabil (2.22) and Flex (0.84). Total debt of $810.4M represents only 8.3% of total assets, suggesting ample borrowing capacity. The rise in debt from $875.2M to $810.4M is modest, but the sequential increase in debt from $772.4M in 2026Q1 to $810.4M in 2026Q2 may indicate a shift toward debt financing to support capacity expansion. Given the low absolute leverage, refinancing risk appears minimal, but investors should monitor whether debt continues to rise as capex needs grow.

The asset mix is becoming more asset-heavy, with PPE growing 78% sequentially from $861.1M to $1.2B, reflecting the capex surge. Goodwill has remained flat around $333M, suggesting no major acquisitions, and intangibles are not a significant concern. This shift toward tangible assets aligns with the company's focus on AI infrastructure, but it also increases fixed costs and depreciation, which could pressure margins if demand softens. The stable goodwill indicates that past acquisitions have not created impairment risk, but the rapid PPE growth warrants monitoring for utilization rates.

The equity base is strengthening, with retained earnings turning positive for the first time in 2025Q3 and reaching $882.0M by 2026Q2. This reflects the company's improved profitability, with net income exceeding cumulative losses. The equity growth from $1.8B to $2.5B is driven by retained earnings, not share issuance, as share repurchases have been modest. This suggests that the company is generating internal capital to fund growth, reducing reliance on external financing. However, the rapid accumulation of retained earnings also implies that the company is not distributing cash to shareholders, which may be a consideration for income-focused investors.

The current ratio has declined from 1.44 in 2025Q2 to 1.23 in 2026Q2, suggesting that current liabilities are growing faster than current assets. This is typical for a company scaling up operations, as payables and accrued liabilities increase with revenue. Cash increased to $535.7M, providing a buffer, but the current ratio is now below the peer average of around 1.5. The quick ratio, excluding inventory, would be lower, given the high inventory levels typical in EMS. While liquidity appears adequate, the trend warrants monitoring, especially if working capital needs continue to rise.